Drug Trial Radar · NCT07500506
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,712
Planned (sponsor's estimate)
Start
Apr 8, 2026
Primary completion
Dec 4, 2026
Study completion Dec 4, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and older, * have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners. * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater). The study will compare the experiences of people receiving the study vaccine or saltwater shot. Participants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.
Conditions
- Lyme Disease
Interventions
VLA15Biological
VLA15 injection IM
PlaceboBiological
Saline Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting prespecified local reactionsTime frame: Within 7 days following each study intervention administration
- Percentage of participants reporting prespecified systemic eventsTime frame: Within 7 days following each study intervention administration
- Percentage of participants reporting adverse events (AEs)Time frame: Through 1 month following study intervention administration
- Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)Time frame: Through study completion, up to approximately 12 months.
- Percentage of participants reporting serious adverse events (SAEs)Time frame: Through study completion, up to approximately 12 months.
- Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)Time frame: At 1 month after completion of Dose 5
- Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).Time frame: At 1 month after completion of Dose 5
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Northern Light Eastern Maine Medical Center
Bangor, Maine · Not yet recruiting
Northern Light Family Medicine and Residency Center
Bangor, Maine · Not yet recruiting
University of Massachusetts Chan Medical School
Worcester, Massachusetts · Recruiting
Hunterdon Medical Center
Flemington, New Jersey · Not yet recruiting
Smith Allergy and Asthma Specialists
Cortland, New York · Recruiting
Smith Allergy & Asthma Specialists
Horseheads, New York · Recruiting
Altoona Center For Clinical Research
Duncansville, Pennsylvania · Recruiting
Allegheny Health and Wellness Pavilion
Erie, Pennsylvania · Recruiting
Central Erie Primary Care
Erie, Pennsylvania · Recruiting
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
Pittsburgh, Pennsylvania · Recruiting
Preferred Primary Care Physicians, Preferred Clinical Research - St.Clair
Pittsburgh, Pennsylvania · Not yet recruiting
Robert Packer Hospital
Sayre, Pennsylvania · Recruiting
Frontier Clinical Research, LLC
Scottdale, Pennsylvania · Recruiting
Northeast Clinical Trials Group
Scranton, Pennsylvania · Recruiting
Frontier Clinical Research, LLC
Smithfield, Pennsylvania · Recruiting
Preferred Primary Care Physicians
Uniontown, Pennsylvania · Not yet recruiting
Velocity Clinical Research, Providence
East Greenwich, Rhode Island · Not yet recruiting
The University of Vermont Medical Center Inc.
Burlington, Vermont · Not yet recruiting
Amherst Family Practice, P.C.
Winchester, Virginia · Not yet recruiting
Milestone Research Inc.
London, Ontario, Canada · Not yet recruiting
Stouffville Medical Research Institute Inc.
Stouffville, Ontario, Canada · Not yet recruiting
Diex Recherche Inc. Division Sherbrooke
Sherbrooke, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.